Summary
Psychedelic compound secretes a psychedelic compound that likes to bind to a different serotonin receptor subtype called 5-HT1A. It has been used clinically to treat vets with post-traumatic stress disorder and is being developed as a treatment for other neurological disorders and drug abuse.
The 5-HT2A receptor mediates the hallucinogenic effects of many popular psychedelics. The drug increased the number of resilient mice. It might provide the basis for a new tryptamine-based mental health treatment as well. One without hallucinatory side effects.
